•ªŽqˆã—ÃŒ¤‹†Žº

 

Žº’·@’†X³“ñ

 

@‹ß”NA“ú–{l‚ÌŽ€–SŒ´ˆö‚Ì‘æ1ˆÊ‚Æ‚È‚Á‚Ä‚¢‚éŠà‚ð‚Í‚¶‚߁A—lX‚È•a‹C‚â•a‘Ô‚ªAˆâ“`Žq‚â’`”’A“œ½‚Æ‚¢‚Á‚½•ªŽq‚ُ̈í‚ÉŠî‚¢‚悶‚邱‚Æ‚ª–¾‚ç‚©‚É‚È‚Á‚Ä‚«‚½BŽÀÛAŠà‚ð—á‚ÉŽæ‚ê‚΁Aˆâ“`Žq‚â‚»‚ÌŽY•¨‚Å‚ ‚é’`”’‚â“œ½‚ُ̈킪A”­‚ª‚ñA‘BA“]ˆÚ‚ÌŠeƒXƒeƒbƒv‚É‚¨‚¢‚ďd—v‚È–ðŠ„‚ð‰Ê‚½‚µ‚Ä‚¨‚èAŒ»Ý‚à—lX‚È•ªŽqˆÙí‚ª•ñ‚³‚ê‚‚‚ ‚éB‚µ‚½‚ª‚Á‚āA‚±‚ê‚ç‚ُ̈핪Žq‚Ì“Á’¥‚â‹@”\‚ð’T‚èA‚ª‚ñ‚Ì—\–h‚âf’fAŽ¡—Âɉž—p‚·‚邱‚Æ‚ÍŠà‚ÌŽ¡—ЬÑ‚ðŒüã‚³‚¹‚éã‚Å‹}–±‚Æ‚È‚Á‚Ä‚«‚Ä‚¢‚éB

@Œ»ÝAŠàŽ¡—Âɂ¨‚¢‚ẮAƒI[ƒ_[ƒƒCƒhˆã—ÂƂ¢‚¤Œê‚É‘ã•\‚³‚ê‚é‚悤‚ɁAŠeŒÂl‚ÌŠà‚ÌŽí—Þ‚â•a‘Ô‚Ì“Á’¥‚ɉž‚¶‚½ˆã—ªŠú‘Ò‚³‚ê‚Ä‚¢‚éB•a‹C‚â•a‘Ԃ̈Ⴂ‚à‘½‚­‚Í•ªŽqˆÙí‚̈Ⴂ‚É‚æ‚Á‚悶‚é‚à‚̂ƍl‚¦‚ç‚ê‚Ä‚¢‚éB‚»‚±‚ŁA–{Œ¤‹†Žº‚ł́AŠà‚É‚¨‚¯‚镪ŽqˆÙí‚ð’T‚èA‚»‚ê‚ÉŠî‚¢‚½V‚½‚ÈŠà‚̐f’f‚⎡—Ð헪‚ÌŠJ”­‚ð‚ß‚´‚µ‚½translational@research‚ðs‚Á‚Ä‚¢‚éB‚»‚Ì‚½‚ß‚Ì‹ï‘Ì“IƒvƒƒZƒX‚Æ‚µ‚āA1) Šî‘bŒ¤‹†‚Æ‚Ì—L‹@“I‚È‹¤“¯Œ¤‹†F—Տ°Þ—¿‚ð—p‚¢‚Ä“¾‚ç‚ꂽŒ¤‹†Œ‹‰Ê‚ƗՏ°Ž‘—¿‚Ƃ̑ΉžA—Տ°Þ—¿‚ð—p‚¢‚½–Ô—…“Iˆâ“`Žq‰ðÍ‚â–Ô—…“Iƒyƒvƒ`ƒh’`”’‰ðÍ‚ð—˜—p‚µ‚½”­ŠàA‘BA“]ˆÚ‚ÉŠÖ‚í‚éÓ”C•ªŽq‚Ì’ŠoA“¯’èB2) •ªŽqˆÙí‚ÉŠî‚¢‚½V‚½‚ÈŽîᇃ}[ƒJ[‚ÌŠJ”­B3) R‚ª‚ñÜ‚â•úŽËüŽ¡—Â̊´Žó«‚â‘ϐ«‚ÉŠÖ—^‚·‚镪Žq‚Ì•ª—£‚Æ‚»‚̗Տ°‰ž—p‚ðŒv‰æ‚µ‚Ä‚¢‚éB‚³‚ç‚ɁA‚±‚ê‚ç‚̐¬‰Ê‚ð‰ž—p‚·‚ׂ­A‘S‘‹K–Í‚Ì‘½Ž{Ý‹¤“¯‚̗Տ°ŽŽŒ±‚⎡Œ±‚ɐϋɓI‚ÉŽQ‰Á‚µ‚Ä‚¢‚éB

y2007”N“xŒ¤‹†”­•\‹ÆÑz

A-0

ARAI I, NAGANO H, KONDO M, YAMAMOTO H, HIRAOKA N, SUGITA Y, OTA H, YOSHIOKA S, NAKAMURA M, WADA H, DAMDINSUREN B, KATO H, MARUBASHI S, MIYAMOTO A, TAKEDA Y, DONO K, UMESHITA K, NAKAMORI S, WAKASA K, SAKON M, MONDEN M.FOverexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion. Hepatogastroenterology 54(73):167-171, 2007

 

CHfNG E, TOMITA Y, ZHANG B, HE J, HOSHIDA Y, QIU Y, MORII E, NAKAMICHI I, HAMADA K, UEDA T, AOZASA K.FPrognostic significance of CD100 expression in soft tissue sarcoma. Cancer 110(1): 164-172, 2007

 

DAMDINSUREN B, NAGANO H, WADA H, KONDO M, OTA H, NAKAMURA M, NODA T, NATSAG J, YAMAMOTO H, DOKI Y, UMESHITA K, DONO K, NAKAMORI S, SAKON M, MONDEN M.FStronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol 30(1):201-208, 2007@

 

KAWAI A, HOSONO A, NAKAYAMA R, MATUMINE A, MATSUMOTO S, UEDA T, TSUCHIYA H, BEPPU Y, MORIOKA H, YABE H.; Japanese Musculoskeletal Oncology Group: Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer 109(1): 109-116, 2007

 

MARUBASHI S, DONO K, NAGANO H, ASAOKA T, HAMA N, KOBAYASHI S, MIYAMOTO A, TAKEDA Y, UMESHITA K, MONDEN M.FPostoperative hyperbilirubinemia and graft outcome in living donor liver transprantation. Liver Transplant 13: 1538-1544, 2007

 

MATSUYAMA J, DOKI Y, YASUDA T, MIYATA H, FUJIWARA Y, TAKIGUCHI S, YAMASAKI M, MAKARI Y, MATSUURA N, MANO M, MONDEN M.FThe effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141: 570-80, 2007

 

MIYOSHI Y, KUROSUMI M, KUREBAYASHI J, MATSUURA N, TAKAHASHI M, TOKUNAGA E, EGAWA C, MASUDA N, KIM SJ, OKISHIRO M, YANAGISAWA T, UEDA S, TAGUCHI T, TAMAKI Y, NOGUCHI S.: From the Collaborative Study Group of Scientific Research of the Japanese Breast Cancer SocietyTopoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers. @Cancer Lett. 2008 Feb

 

NAGANO H, MIYAMOTO A, WADA H, OTA H, MARUBASHI S, TAKEDA Y, DONO K, UMESHITA K, SAKON M, MONDEN M.FInterferon-ƒ¿ and 5-Fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110: 2493-2501, 2007

 

NAKAHIRA S, NAKAMORI S, TSUJIE M, TAKAHASHI Y, OKAMI J, YOSHIOKA S, YAMASAKI M, MARUBASHI S, TAKEMASA I, MIYAMOTO A, TAKEDA Y, NAGANO H, DONO K, UMESHITA K, SAKON M, MONDEN M.FInvolvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. International Journal of Cancer120:1355-1363,2007

 

NAKAHIRA S, NAKAMORI S, TSUJIE M, TAKEDA S, SUGIMOTO K, TAKAHASHI Y, OKAMI J, MARUBASHI S, MIYAMOTO A, TAKEDA Y, NAGANO H, DONO K, UMESHITA K, SAKON M, MONDEN M.FPretreatment with S-1, an Oral Derivative of 5-Fluorouracil, Enhances Gemcitabine Effects in Pancreatic Cancer Xenografts. Anticancer Research 28(1A):179-186,2008

 

NAKAMURA M, NAGANO H, SAKON M, YAMAMOTO T, OTA H, WADA H, DAMDINSUREN B, NODA T, MARUBASHI S , MIYAMOTO A, TAKEDA Y, UMESHITA K, NAKAMORI S, DONO K, MONDEN M.FRole of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.  J Hepatol 46(1):77-88, 2007

 

OBATA H, UEDA T, KAWAI A, ISHII T, OZAKI T, ABE S, TANAKA K, TSUCHIYA H, MATSUMINE A, YABE H.FClinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 109(4): 767-775, 2007

 

TAKENAKA S, UEDA T, NAKA N, ARAKI N, HASHIMOTO N, MYOUI A, OZAKI T, NAKAYAMA T, TOGUCHIDA J, TANAKA K, IWAMOTO Y, MATSUMINE A, UCHIDA A, IEGUCHI M, KAYA M, WADA T, BABA I, KUDAWARA I, AOKI Y, YOSHIKAWA H.FPrognostic implication of SYT-SSX fusion type in synovial sarcoma: A multi-institutional retrospective analysis in Japan. Oncol Rep 19(2): 467-476, 2008

 

TOI M, NAKAMURA S, KUROI K, IWATA H, OHONO S,MASUDA N, KUSAMA M,YAMAZAKI K, HISAMATSU M, SATO Y, KASHIWABA MAKAISE H, KUROSUMI M, TSUDA H, AKIYAMA F,OHASHI Y, TAKATSUKA Y.@:@Phase ‡U@Study of preperative sequential FEC and docetaxel predictsw of pathological response and desease free survival.Breast Cancer Res Treat,2007

 

TOYOSAWA S, YUKI M, KISHINO M, OGAWA Y, UEDA T, MURAKAMI S, KONISHI E, IIDA S, KOGO M, KOMORI T, TOMITA Y.FOssifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization. Modern Pathol 20(3): 389-396, 2007

 

TSUJIE M, NAKAMORI S, NAKAHIRA S, TAKAHASHI Y, HAYASHI N, OKAMI J, NAGANO H, DONO K, UMESHITA K, SAKON M, MONDEN M.FHuman equilibrative nucleoside transporter 1,as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Research 27(4B):2241-2250,2007

 

UCHIDE K, SAKON M, ARIYOSHI H, NAKAMORI S, TOKUNAGA M, MONDEN M.FCancer cells cause vascular endothelial cell (VEC) retraction via 12 (S)HETE secretion; the possible role of cancer cell derived microparticle. Annals of Surgical Oncology 14(2):862-868,2007

 

WADA H, NAGANO H, YAMAMOTO H,  ARAI I, OTA H, NAKAMURA M, DAMDINSUREN B, NODA T, MARUBASHI S, MIYAMOTO A, TAKEDA Y, UMESHITA K, DOKI Y, DONO K, NAKAMORI S, SAKON M, MONDEN M.FCombination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.  Oncol Rep 18(4):801-809, 2007

 

YAMAMOTO T, NAGANO H, IMAI Y, FUKUDA K, MATSUMOTO H, KONDO M, OTA H, NAKAMURA M, WADA H, NODA T, DAMDINSUREN B, DONO K, UMESHITA K, NAKAMORI S, SAKON M, WAKASA K, MONDEN M.FSuccessful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. International Journal of Clinical Oncology 12(2):150-154,2007

 

YANG Y, NAGANO H, OTA H, MORIMOTO O, NAKAMURA M, WADA H, NODA T, DAMDINSUREN B, MARUBASHI S, MIYAMOTO A, TAKEDA Y, DONO K, UMESHITA K, NAKAMORI S, WAKASA K, SAKON M, MONDEN M.FPatterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141(2):196-202, 2007

 

A-1

‘“cTŽOFu‚ª‚ñŠ³ŽÒƒPƒAQ&A|“û‚ª‚ñÁ‰»Ší‚ª‚ñ‚Ì–ò•¨—Ö@‚𒆐S‚ɁviŠÄCjA3-8A‚¶‚Ù‚¤A2007”N

 

A-2

•ìK“TF5. —Տ°ŽŽŒ±|3. —LŒø«‚ƈÀ‘S«‚Ì•]‰¿AuV—Տ°Žîᇊw|‚ª‚ñ–ò•¨—Ö@ê–åˆã‚Ì‚½‚߂Ɂv“ú–{—Տ°Žîᇊw‰ï•ÒA133-137A“ì]“°

 

•ìK“TF7. Ž¡–ü‚ð–ÚŽw‚µ‚½ˆÝ‚ª‚ñ‚ÌŽ¡—Á|‡Ep‘O•â•—Ö@‚̐V‚µ‚¢ŽŽ‚Ý‚Æ‚»‚̈ʒu‚¯AuƒCƒ“ƒtƒH[ƒ€ƒhƒRƒ“ƒZƒ“ƒg‚Ì‚½‚߂̐}àƒVƒŠ[ƒYiˆÝ‚ª‚ñjvA82-87Aˆã–òƒWƒƒ[ƒiƒ‹ŽÐ

 

‘“cTŽOF–ò•¨—Ö@‚̍l‚¦•ûBu‚ª‚ñŠ³ŽÒƒPƒAQ&A|“û‚ª‚ñÁ‰»Ší‚ª‚ñ‚Ì–ò•¨—Ö@‚𒆐S‚Ɂvi•ª’SŽ·•MjA3-8A‚¶‚Ù‚¤A2007”N

 

‘“cTŽOFp‘O–ò•¨—Ö@‚̃‚ƒjƒ^ƒŠƒ“ƒOBŽÀ‘H“û–[’´‰¹”gf’f\Šî–{‘€ìA“ljeAÅVƒeƒNƒjƒbƒN@A249-254A’†ŽR‘“XA2007”N

 

‘“cTŽOF‰ÈŠw“Iª‹’‚ÉŠî‚­“ûŠàf—ÃKƒCƒhƒ‰ƒCƒ“i2004|2007ju¡“ú‚ÌŽ¡—ÃŽwj2008vA1599|1606AˆãŠw‘‰@A“Œ‹žA2008”N

 

‘“cTŽOFŽ¡—Öò‚ÌŽí—Þ‚Æ“Á’¥iR‚ª‚ñÜjuƒCƒ“ƒtƒH[ƒ€ƒhƒRƒ“ƒZƒ“ƒg‚Ì‚½‚߂̐}àƒVƒŠ[ƒY@“û‚ª‚ñ–ò•¨—Ö@vŒËˆä‰ë˜a•ÒWA48-59Aˆã–òƒWƒƒ[ƒiƒ‹ŽÐA‘åãA2008”N

 

A-3

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FA”ú±³Ž÷A•½”ö‘fGA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­FPagetoid spread‚𔺂Á‚½ãè–åŠÇ‘BŠà‚Ì1—áA“ú–{ŠO‰ÈŒn˜A‡Šw‰ï32(1):74-77A2007

 

”—t‹§Š°, ”—t‹§Š°AŽá—э„A’†‘º´ŒáA•ˆäŽ¹AŠâ“cL–èA‘å–ì^ŽiA‘“cTŽOA²“¡MºA–ƒ‰ê‘¾˜YAŽR–{®lAÂ‹VŒ’“ñ˜YA²“¡NKA•Z¹ŽjA’Óc‹ÏAHŽR‘¾AŒËˆä‰ë˜a: “ÁW@p‘O–ò•¨—Ö@‚Ìbreak through@JBCRG03:Docetaxel 75mg/m2 followed by FEC 100mg/m2‚É‚æ‚ép‘O‰»Šw—Ö@-JBCRG01,02‚©‚ç‚Ìreview ‚Æbreak throughA“ûŠà‚̗Տ° A22(5)F372-375A2007

 

•ìK“TA•Ÿ“cŽ¡•FFƒAƒƒŠƒJNCI‚É‚¨‚¯‚éTRŽx‰‡‘̐§ADrug Delivery System 2007  22: 54-59A2007

 

ŒÃÈ‰Ãˆê@‰““¡“oŠìŽq,@Šâ£‘ñŽmA‰F’Öì‰hA‘åŠÑK“ñA“Œ–ì‰p—˜ŽqAŠp“c”ŽŽqA‘呺•õ•vAŠ}Œ´‘P˜YA@‘“cTŽOA@ì“‡”ŽŽqA—é–؏º•FA“c‘ºŒ³A“¡Œõ—¥ŽqAX–{’‰‹»@: ƒAƒ“ƒP[ƒg’²¸‚É‚æ‚éƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒB“ljeuK‰ï‚̐¸“xŠÇ—u‡FvA“ú–{“ûŠàŒŸfŠw‰ïŽ 15i3jF268-283A2007

 

’|’†”üŽ÷A‰ª–{’õWA’r“cŒ«“ñA‹´–{@—ˁAã“cF•¶A•ìM•vA‚–Ø’B–çAã“‡‰xŽqF®Œ`ŠO‰È—̈æ‚É‚¨‚¯‚é‘å—ÊŠà‰»Šw—Ö@‚ɑ΂·‚é5-HT3Žó—e‘̝hRÜ‚ÌŒø‰Ê”äŠrAŠà‚Ɖ»Šw—Ö@ 34(3): 403-407A2007

 

—с@i•¶AX“àG—SA”öè—F•FA‚Š_‹§ŽõAƒ‚ƒŠƒXEƒVƒFƒCƒ“A”W’†³”ŽAŽR’†ˆêŒ÷A ’†“‡LAŽRè–ƒ”üA^”\³KA’|“c‰ëŽiAã•½’©ŽqF–ƉuˆÙí‚ɍ‡•¹‚µAˆ««ƒŠƒ“ƒpŽî‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚½”]“à•a•Ï‚Ì5—áA ”]_ŒoŠO‰È‘¬•ñ17: 855-861A2007

 

ŒÃì‡NA‚’Ë—YˆêAh@‰h¬A‘“cTŽOAŒõŽR¹ŽìA¬¼–LA¼ìG•¶A‹{“àŒ[•ãA‘O‰Y‹`ŽsAŽR–{mA‹{‰ºŸA‘åÎ‰ë—mA–쑺FAŽR’†‰pŽ¡Aæ“cŒ÷A–k“c¹”V: •ÂŒoŒã‘Šú“ûŠàiT…3cmANOj‚ɑ΂·‚éãüâ|ƒŠƒ“ƒpßŠs´‚Æ”ñŠs´‚Ì”äŠrŽŽŒ±A“ûŠà‚̗Տ° 22i 5jF 434-435A 2007

 

‘“cTŽOAŒËˆä‰ë˜aA‚’Ë—YˆêA’†‘º´ŒáAŠâ“cL–èA‘å–ì^ŽiA•ˆäŽ¹A“ú”nŠ²OA‹v¼˜aŽjAŽRèOŽ‘Ah@‰h¬A²“¡NKAŠC£”ŽŽjA”—t‹§Š°AŠâ£OŒhA•Z¹ŽjA’Óc@‹ÏAHŽR@‘¾: “ûŠàŽüpŠú‰»Šw—Ö@‚ÌŒ»ó‚¨‚æ‚ÑSupportive Care‚̍H•v-JBCRG01ƒAƒ“ƒP[ƒg‚æ‚èA‚ª‚ñ‚Ɖ»Šw—Ö@34F1609-1615 A2007

 

A-4

“àŠC“ŠGAŽR“c³ŒÈA´…ŽOA‹{–{“ÖŽjA”~‰º_ŽiA¬—Ñ“N˜YA–å“cŽçlA–q–{´ŽqFÁ‰»ŠíŠO‰ÈŽèp‚É‚¨‚¯‚éŽèp•”ˆÊŠ´õ‚̃ŠƒXƒNˆöŽq‚ÌŒŸ“¢AŠÂ‹«Š´õ 22(4): 294-298A 2007

 

‘½ªˆä@’q‹I,‘“cTŽOAÎ”ò^lAŒË‚Œ¦‘ãA“c’†“o”üAã–ì—T”V: “ûŠà-Šî‘b¥—Տ°Œ¤‹†‚̃Aƒbƒvƒf[ƒg@‡X@Ž¡—Á@Še˜_@‰»Šw—Ö@@ŠO—ˆ’ʉ@‚É‚æ‚鉻Šw—Ö@A“ûŠà[Šî‘bE—Տ°‚̃Aƒbƒvƒf[ƒg165i6jF535-541A2007

 

’†X³“ñA’ҍ]³“¿A‹{–{“ÖŽjAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­FäXŠàäXŠà‚̍Ĕ­f—ÂɊւ·‚éÅV‚̃f[ƒ^A—Տ°ŠO‰È62(11):327-335A2007

 

’†X³“ñA’ҍ]³“¿A”ú±³Ž÷AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­A‹{–{“ÖŽjA•“c@—TA–å“cŽçlFäXŠà‚Ì•úŽËü‰»Šw—Ö@AŠO‰ÈŽ¡—Ã97(3):292-299A2007

 

’†X³“ñA”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­A’†•½@LA’ҍ]³“¿A•“c@—TA–å“cŽçlFäXŠà‰»Šw—Ö@‚É‚¨‚¯‚égemcitabine—LŒø«Œüã‚Ì‚½‚ß‚ÌŠî‘b“IE—Տ°“IŒŸ“¢AäX‘Ÿ 22(1):21-25A2007

 

’†X³“ñFŠÌ×–EŠà‚Ì”­¶Ei“W‚¨‚æ‚ÑŠÌ“]ˆÚ‚ÉŠÖ—^‚·‚éˆâ“`ŽqAÅVˆãŠw(‘Š§†):699-712A2007

 

’†X³“ñF’_“¹ŠàAƒRƒ“ƒZƒ“ƒTƒXŠàŽ¡—Ã6(3):141-143A2007

 

’†X³“ñA“Œ@^—ŽqFäX‘Ÿ‚̈««Ž¾Š³AÁ‰»ŠíŠO‰ÈNURSINGit‹G‘Š§j:200 - 204 A2008

 

’†X³“ñA“Œ@^—ŽqFäX‘Ÿ‚̗ǐ«Ž¾Š³AÁ‰»ŠíŠO‰ÈNURSINGit‹G‘Š§j:191-199 A2008

 

’†X³“ñA™Œ³—¢“ށFäXØœp AÁ‰»ŠíŠO‰ÈNURSINGit‹G‘Š§j:273-278 A2008

 

–ì“c„LA‰i–ì_ºA‘ºã¹—TA¬—яȌáAŠÛ‹´@”ɁA‹{–{“ÖŽjA•“c@—TA“°–ìŒbŽOA”~‰º_ŽiAŽá‹·Œ¤ˆêA–å“cŽçlF ŠÌ×–EŠà‚ÌŒo”ç“IŽ¡—ÃŒã‚Ì• o“à‚¨‚æ‚ѐúŽhŒo˜H”dŽí‚ɑ΂·‚éŠO‰È“IØœ‚Ì—LŒø«AŠà‚Ɖ»Šw—Ö@ 34(12): 2080-2083A2007

 

“¡’J˜a³A’Ò’‡—˜­A‹{Š_”Ž“¹A•ìK“TA•½”ö‘fGA’ҍ]³“¿AˆÀˆä¹‹`A‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñF”ñŽ¡–üˆÝŠà‚ɑ΂·‚éŠO‰ÈŽ¡—ÁAŠO‰ÈŽ¡—Ã97(4):393-399A2007

 

‘“cTŽOAÎ”ò^lAŒË‚Œ¦‘ãA“c’†“o”üAã–ì—T”V: ‡X@Ž¡—Á@Še˜_@‰»Šw—Ö@@Žèp•s”\‚Ü‚½‚͍Ĕ­“ûŠà‚̍œK‰»Šw—Ö@A“ûŠà\Šî‘bF—Տ°‚̃Aƒbƒvƒf[ƒg165 i6jF523-529A2007

 

‘“cTŽO: ASCOƒTƒ}ƒŠ[@:“û‘BŽîᇕª–ìB‚ª‚ñ•ªŽq•W“IŽ¡—à 5(4):37-43A2007

 

‘“cTŽO: Current Organ topics -“ûŠà-A“ûŠàŽ¡—Âɂ¨‚¯‚éÅ‹ß‚̐i•à ŒÂ•Ê‰»Ž¡—Âւ̒§í(‘åã)A34i13jF2228-2235A2007

 

‘“cTŽO: “û‚ª‚ñ‚̐f’f‚ÆŽ¡—Á@“û‚ª‚ñŽ¡—Â̍őOüA“ú–{•úŽËü‹ZpŠw‰ï‹ß‹E•”‰ïŽGŽ13i1jF40-43A2007

 

‘“cTŽO: “û‚ª‚ñŽ¡—Â̌»ó‚Æ“W–]EŒÂ•Ê‰»Ž¡—Âð–ÚŽw‚µ‚āA‘‡—Տ° 56i11jF3103-3105A2007

 

‘“cTŽO: “ûŠà‚ÌÎÙÓݗÖ@@ÅV“®Œü@•ÂŒoŠú¥•ÂŒoŒã“ûŠà‚ɑ΂·‚éƒzƒ‹ƒ‚ƒ“—Ö@AˆãŠw‚Ì‚ ‚ä‚Ý 221i2jF160-164 A2007

 

‹{Š_”Ž“¹A’†X³“ñA”ú±³Ž÷A’r‰i‰ëˆêA’Ò’‡—˜­A^”\³KFäX‰ŠÇó‚É‚æ‚è”­Œ©‚³‚ꂽ¬×–E”xŠàäX“]ˆÚ‚Ì1—áA“ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ69(1):160-165A2008

 

‘ºã¹—TA‰i–ì_ºA–ì“c„LA˜a“c_ŽuA¬—яȌáAŠÛ‹´@”ɁA‹{–{“ÖŽjA•“c@—TA“°–ìŒbŽOA”~‰º_ŽiA–å“cŽçlF Doxorubicine/IFN-ƒÀ•¹—p‰»Šw—Ö@‚Ɗ̐؏œp‚É‚æ‚è’·Šú¶‘¶‚µ“¾‚½‰ES–[“àŽîᇐð‚𔺂¤isŠÌ×–EŠà‚Ì1—áAŠà‚Ɖ»Šw—Ö@ 34(12): 2087-2089A2007

 

˜a“c_ŽuA‰i–ì_ºAŠÛ‹´@”ɁA‹{–{“ÖŽjA–ì“c„LA¬—яȌáA•“c@—TA”~‰º_ŽiA“°–ìŒbŽOA–å“cŽçlFŠÌ×–EŠàØœŒã‚Ì’·Šú¬ÑŒüã‚ð–ÚŽw‚µ‚Ä- 1.p‘OŠÌ“®–¬ÇðpiTAEjAŠO‰È 69(5):497-503A 2007

 

A-6

‘“cTŽO: u“ûŠà‚̏pŒã•â•—Ö@-2007@St.Gallen ƒRƒ“ƒZƒ“ƒTƒX‰ï‹c„§‚𒆐S‚ɁvA“ú–{“ûŠàŠw‰ïŠwp‘‰ïƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€‹L˜^ûŽqA2007”N

 

B-2

AIHARA T, SUEMASU K, TAKEI H, TAKEHARA M, OSUMI S, SAITO T, MASUDA N, OHASHI Y. : The effect of exemestane,anastrozole and tamoxifen on bone mineral density and bone turnover makers in postmenopausal early breast cancer patients.San Antonio Breast Cancer Symposium 2007,@San@Antonio,2007”N12ŒŽ

 

KUROKAWA Y, YAMAGUCHI T, YOSHIMURA K, YAMAMOTO S, NAKAMURA K, SASAKO M, FUKUDA H.FQuantitative evaluation of heterogeneities in treatment effects and baseline risks among hospitals: from a phase III surgical trial of gastric cancer. 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (U.S.A.), 2007”N6ŒŽ

 

TOKUDA Y, KURIYAMA K , NAKAMOTO A, SAI H , YUTANI K,  KUNITOMI Y, HANEDA K., KAWAI M ,  MASUDA N., TAKEDA M. :Evaluation of suspicious nipple discharge by MR mammography based on BI-RADS MRI descriptors@Europian Congress of Radiology. 2008 Vienna, 2008.3.7-11

 

UEDA T, KAKUNAGA S, OKA Y, OJI Y, TSUBOI A, HASHIMOTO N, MYOUI A, AOZASA K, SUGIYAMA H, YOSHIKAWA H.FTumor Immunotherapy Targeting WT1(Wilms' Tumor Gene) Peptide for Bone and Soft-Tissue Sarcomas: A Preliminary Report. 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (U.S.A.), 2007”N6ŒŽ

 

UEDA T, KAKUNAGA S, TSUBOI A, SUGIYAMA H, YOSHIKAWA H.FTumor Immunotherapy Using WT1(Wilms' Tumor Gene) Peptide Vaccine for Bone and Soft-Tissue Sarcomas: A Preliminary Report. 5th SICOT/SIROT Annual International Conference, Marrakech, 2007”N8ŒŽ

 

UEDA T, KUDAWARA I, KAKUNAGA S, TAMAI N, HASHIMOTO N, MYOUI A, HAMADA K, FUJIMOTO T, NAKA N, ARAKI N, AOKI Y, YOSHIKAWA H.FClinical Outcome of Limb-Sparing Surgery for Patients with Osteosarcoma of Proximal Tibia. 59th Annual International Congress of the Egyptian Orthopaedic Association (EOA), Cairo, 2007”N11ŒŽ

 

VAN NES JGH, SMIT VTHBM, PUTTER H, KUPPEN PJ ,KIM SJ, MASUDA N, INAJI H, YOSHIDOME K, TSUJIMOTO M, AKIYAMA F, TSUKAMOTO F, ISHIHARA H, NOGUCHI S, VAN DE VELDE CJH. : Cyclin –independent kinase 1 and 2 activity as prognostic makers in early breast cancer. San Antonio Breast Cancer Symposium 2007,@San@Antonio,2007”N@12ŒŽ

 

B-3

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAÎ”ò^lA‘“cTŽOA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­FŽ©“®•«‡Ší‚ð—p‚¢‚½’¼’°ŠàŽèp‚É‚¨‚¯‚éƒsƒbƒgƒtƒH[ƒ‹‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒOB ‘æ32‰ñ “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïA“Œ‹žA2007”N6ŒŽ

 

ã“cF•¶AŠO–x@ŽiA”ö˜H—S‰îA•y“c—T•FAŠp‰i–ÎŽ÷A–¼ˆä@—zAÂùŽ”VA™ŽRŽ¡•vA‹gìGŽ÷FœE“î•”“÷Žî‚É‚¨‚¯‚éWT1ˆâ“`Žq”­Œ»‚̈Ӌ`B‘æ96‰ñ“ú–{•a—Šw‰ï‘‰ïA‘åãA2007”N3ŒŽ

 

ã“cF•¶FœE“î•”ˆ««Žîᇂɑ΂·‚éWŠw“IŽ¡—Ñ̌n‚̐i•à‚Æ‚»‚̍őOüB‘æ80‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwpW‰ï ‹³ˆçŒ¤Cu‰‰A_ŒËA2007”N5ŒŽ

 

ã“cF•¶C–î•”Œ[•vFœE“î•”ˆ««Žîᇂɑ΂·‚鑽Ž{Ý‹¤“¯Œ¤‹†‚ÌŒ»ó‚ƍ¡Œã‚Ì“WŠJ-œE“î•”“÷ŽîŽ¡—ÃŒ¤‹†‰ïiJMOG)‚Å‚ÌŒoŒ±‚𒆐S‚É-B‘æ40‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïœE“î•”ŽîᇊwpW‰ïAb•{A2007”N7ŒŽ

 

ã“cF•¶F®Œ`ŠO‰È—̈æ‚̈««Žîᇁ|“÷Žî‚̐f’f‚ÆŽ¡—Á|B‘æ45‰ñ“ú–{ŠàŽ¡—Êw‰ï‘‰ï ‹³ˆçƒZƒbƒVƒ‡ƒ“¢‚ª‚ñŽ¡—Ãupdate£A‹ž“sA2007”N10ŒŽ

 

ã“cF•¶FœE“î•”ˆ««Žîᇂɑ΂·‚éWŠw“IŽ¡—Ñ̌n‚̐i•àB‘æ19‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï œ“î•”•úŽËüŒ¤‹†‰ïE•ÐŽR‹L”Ou‰‰A‹ž“sA2008”N1ŒŽ

 

”—t‹§Š°AŽá—с@„A’†‘º´ŒáA•ˆäŽ¹AŠâ“cL–èA‘å–ì^ŽiA‘“cTŽOA²“¡MºA–ƒ‰ê‘¾˜YA@ŽR–{®lAÂ‹VŒ’“ñ˜YA@²“¡NKA•Z¹ŽjA’Óc‹ÏAHŽR@‘¾AŒËˆä‰ë˜a: ƒvƒŒƒWƒfƒ“ƒVƒƒƒ‹ƒVƒ“ƒ|ƒWƒEƒ€2@JBCRG03FDocetaxel followed@byFEC100‚É‚æ‚ép‘O‰»Šw—Ö@F@JBCRG01,02‚©‚ç‚Ìreview‚ÆbreakthoughB ‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï A‰¡•lA2007”N6ŒŽ

 

”ú±³Ž÷A‘呺mºA¼“c®OAˆÀ’B’q—mAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F“–‰È‚É‚¨‚¯‚éŒn““ISSI‘΍ô\‹ts«Š´õ‘΍ô‚©‚çƒRƒXƒgíŒ¸‚܂ŁB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

–؉º‹M”VA¡ˆäí•vA‘åŠÑK“ñA²–ì@–¾A—é–ؐ³lA“c‘º˜a•vA“yˆäŒ´”Ž‹`A‘“cTŽOAŠâ£‘ñŽm: ƒ[ƒNƒVƒ‡ƒbƒv2@“ú–{“ûŠàŠw‰ï‘S‘“û‚ª‚ñ“o˜^‚̐V‹KƒVƒXƒeƒ€‚ÌŽÀÛ‚ƍ¡Œã‚Ì“W–]B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

•ìK“TA²“¡‹Å—mA‹g‘ºŒ’ˆêA’†‘ºŒ’ˆêAâV“¡@—EAŽR–{¸ˆê˜YA•Ÿ“cŽ¡•FFÁ‰»ŠíŠà‚ÌŽèpŽè‹Z‚ð•]‰¿‚·‚éJCOG—Տ°ŽŽŒ±‚ÌŒ»óB‘æ107‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA‘åãA2007”N4ŒŽ

 

’Ò’‡—˜­A“¡’J˜a³A•½”ö‘fGAŽO“ˆGsA’r‰i‰ëˆêA‹{è“¹•FAˆÀˆä¹‹`A’†X³“ñA”ú±³Ž÷A‚Œ©N“ñA@‘“cTŽOA@ŽR‘º@‡Fƒ`[ƒ€‚ÅŽx‚¦‚éŽüpŠú‰h—{ŠÇ—\ƒGƒrƒfƒ“ƒX‚ðŽÀ‘H‚·‚邽‚߂ɁB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

•½”ö‘fGA’Ò’‡—˜­A“¡’J˜a³A’†X³“ñAŽO“ˆGsA‚Œ©N“ñA‹{è“¹•FA’r‰i‰ëˆêA‘“cTŽOAˆÀˆä¹‹`AŽR‘º@‡A‘å‹{‰p‘ׁA’ҍ]³“¿FˆÝŠà—H–呤ˆÝØœŒãAR-YÄŒš–@versus ƒÏŒ^•«‡•t‰ÁR-YÄŒš–@‚ÉŠÖ‚·‚郉ƒ“ƒ_ƒ€‰»‘OŒü‚«”äŠr—Տ°ŽŽŒ±ÅI•ñB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ŒÃì‡NAŒÃÈ‰ÃˆêA‘“cTŽOA’†’JŽçˆêA¼•À“W‹PA”¨”W••FA’†“‡’¼A’|ì’¼ÆA–{“cˆçŽqA“cŒû“N–çA¼@•q•vAŽ›“c@‰›A–퐶@ŒbŽi: ƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒBiMMGjŒŸf‚ÌŽóf—¦Œüãô‚ÌŒŸ“¢-‘åã•{‚ÌŒŸf¸“xŠÇ—’²¸‚©‚ç-B“ú–{“û‚ª‚ñŒŸfŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ 

 

‘“cTŽO: ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€3@“ûŠà‚̏pŒã•â•—Ö@`2007@St@Gallen ƒRƒ“ƒZƒ“ƒTƒX‰ï‹c„§‚𒆐S‚Ɂ@-•ÂŒo‘O“à•ª”å—Ö@-B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï A‰¡•lA2007”N6ŒŽ

 

‘“cTŽO: ¢“û‚ª‚ñ‰»Šw—Ö@‚ðˆÀ‘S‚ÉŽÀŽ{‚·‚邽‚߂Ɂ`‚ ‚È‚½‚Í‘åä•v‚Å‚·‚©H`“ûŠà‰»Šw—Ö@‚̍ŐVî•ñvB‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[ A‰¡•lA2007”N6ŒŽ

 

‘“cTŽO: ASCO-BC“ûŠàÅVî•ñTVƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX‚Å‚Ì•ñB  ONC TVƒVƒ“ƒ|ƒWƒEƒ€A‹ž“sA2007”N10ŒŽ@

 

^”\³KFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[F‘ŸŠí•ÊÅ“KHEõFðŒ‚ÌŒŸ“¢B‘æ53‰ñ“ú–{•a—Šw‰ïHŠú“Á•Ê‘‰ïA“Œ‹žA2007”N12ŒŽ

 

ŽODN—YA–ìŒûáÁŽO˜YA@•Z¹ŽjAg—я~ˆêA@¼‰Y¬º@A‚‹´«lA“¿‰i‚¦‚èŽqA•¿ìç‘ã”üA@‘“cTŽO: ƒvƒŒƒWƒfƒ“ƒVƒƒƒ‹ƒVƒ“ƒ|ƒWƒEƒ€2@p‘O‰»Šw—Ö@‚É‚¨‚¯‚銴Žó«—\‘ªˆöŽq‚Ì“¯’èB‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï A‰¡•lA2007”N6ŒŽ

 

B-4

H“c—TŽjA•“c@—TA’†X³“ñAŠÛ‹´@”ɁA‹{–{“ÖŽjA‰i–ì_ºA–kì@“§A“°–ìŒbŽOA”~‰º_ŽiA–å“cŽçlF“–‰È‚É‚¨‚¯‚éäXŠÇ“à“û“ªŽîᇁiIPMNjŽèpÇ—á‚ÌŒŸ“¢B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

ˆÀ’B’q—mA‘“cTŽOAÎ”ò^lA’|“c‰ëŽiA^”\³KA’†X³“ñA’Ò’‡—˜­FTriple negativeÇ—á‚ÌŒŸ“¢B ‘æ15 ‰ñ “ú–{“ûŠàŠw‰ïŠwpW‰ïA‰¡•lA2007”N6ŒŽ

 

ˆÀ’B’q—mA‘“cTŽOAŽR‘º@‡A’ҍ]³“¿AˆÀˆä¹‹`A‘å‹{‰p‘ׁA‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³A‚Œ©N“ñA’†X³“ñA’Ò’‡—˜­FTriple negativeÇ—á‚̗Տ°“IŒŸ“¢B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ˆÀ’B’q—mA•½”ö‘fGA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F”äŠr“I‘Šú‚É”­Œ©‚µ‚¦‚½\“ñŽw’°Šà‚Ì1—áB ‘æ182‰ñ ‹ß‹EŠO‰ÈŠw‰ïA‘åãA2007”N12ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAÎ”ò^lA‘“cTŽOA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‚ª‚ñê–åŽ{Ý‚Å‚Ì• •”‹Ù‹}ŽèpÇ—á‚ÉŠÖ‚·‚錟“¢B ‘æ32‰ñ “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïA“Œ‹žA2007”N6ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‘å’°ŠàŽèp‚É‚¨‚¯‚é“à‘ŸŽ‰–bƒŒƒxƒ‹‚Ì‘ª’è\ˆÀ‘S‚ÈŽèpŒv‰æ‚Ì—\‘ªˆöŽq\B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‚ª‚ñê–åŽ{Ý‚É‚¨‚¯‚é• •”‹Ù‹}ŽèpÇ—á‚ÌŒ»óB ‘æ45‰ñ “ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A”ú±³Ž÷A‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA”’”©LGA’r“c¹OA’Ò’‡—˜­F‘å’°ŠàŽ¡—ÃKƒCƒhƒ‰ƒCƒ“‚ɑ΂·‚éÁ‰»ŠíŠO‰ÈE“à‰Èˆã‚Ì”FŽ¯‚Æ–â‘è“_B ‘æ49‰ñ “ú–{Á‰»Ší•aŠw‰ï‘å‰ïA_ŒËA2007”N10ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FA’†X³“ñA’Ò’‡—˜­F‚ª‚ñê–åŽ{Ý‚É‚¨‚¯‚é• •”‹Ù‹}ŽèpÇ—á‚ÌŒ»ó‚Ɖº•”Á‰»ŠÇŠO‰Èˆã‚Ì‹‡óB ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FA’†X³“ñA’Ò’‡—˜­FŒ‹’°ŠàŽèp‚É‚¨‚¯‚éisoperistaltic lateral anastomosis(side to side anastomosis)B ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA”ú±³Ž÷A‘å‹{‰p‘ׁA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­A‹gìé‹PF’¼’°ŠàŽèp‚É‚¨‚¯‚邱‚¾‚í‚è‚Ì’¼’°çê|‹ž‘å•wl‰ÈŽ®’¼’°çê‚Æ’¼’°‚ׂç|B ‘æ69 ‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA”ú±³Ž÷A‘å‹{‰p‘ׁA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‚ª‚ñê–åŽ{Ý‚É‚¨‚¯‚é• •”‹Ù‹}ŽèpÇ—á‚ÌŒ»ó‚Ɖº•”Á‰»ŠÇŠO‰Èˆã‚Ì‹‡óB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA”ú±³Ž÷A‘å‹{‰p‘ׁA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‘å’°ŠàŽèp‚É‚¨‚¯‚邱‚¾‚í‚è|’°•ÂÇ—\–h‚Æ‘nŠ´õ‰ñ”ð‚̍H•v|B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•l 2007”N11ŒŽ]12ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA”ú±³Ž÷A‘å‹{‰p‘ׁA•½”ö‘fGA“¡’J˜a³A‚Œ©N“ñA’†X³“ñA’Ò’‡—˜­F“à‘ŸŽ‰–b‚ª‘å’°ŠàŽèp‚É—^‚¦‚é‰e‹¿|ˆÀ‘S‚ÈŽèpŒv‰æ‚Ì—\‘ªˆöŽq|B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

’r‰i‰ëˆêAŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA”ú±³Ž÷A‘å‹{‰p‘ׁA•½”ö‘fGA“¡’J˜a³A‚Œ©N“ñA’†X³“ñA’Ò’‡—˜­F–D‡•s‘Sƒ[ƒ‚ð‚ß‚´‚µ‚½Œ‹’°ŠàŽèp‚É‚¨‚¯‚éisoperistaltic lateral anastomosis(side to side anastomosis)B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

’r‰i‰ëˆêA’Ò’‡—˜­AŽO“ˆGsAˆÀˆä¹‹`A‹{è“¹•FAŽR‘º@‡A’ҍ]³“¿A‘“cTŽOA‘å‹{‰p‘ׁA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñF‘å’°ŠàŽèp‚É‚¨‚¯‚éƒNƒŠƒJƒ‹ƒpƒX|‘ŠúŒoŒûÛŽæ‚ÌŽæ‚è‘g‚݁|B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

Î“cFéA‘å“àŒ›–¾A•“cŒ³”ŽA–ìŒûáÁŽO˜Y@A•Ÿ“‡‰ë“TA@‚’Ë—YˆêA@‘“cTŽOA¼‘º—ߊìA“V–ìŒá˜Y: ƒAƒ“ƒgƒ‰ƒTƒCƒNƒŠƒ“Aƒ^ƒLƒTƒ“•s‰ž«“]ˆÚ«“ûŠà‚ɑ΂·‚éƒgƒ‰ƒXƒcƒYƒ}ƒu‚ƃJƒyƒVƒ^ƒrƒ“•¹—p—Ö@‚̈À‘S«•]‰¿B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

Î’ËXŠÛAŽRŒË¹Ž÷A¬ŒüŒ«ˆêA²X–Ø“TŽqAŽRŒ³”Ž‹`AœA‰ªŒcŽ¡A’@Žá•xAìŒû‹`œAAˆÀ‘º—Ç’jA“퉪‰p—YA¥P”VGAÎâ@“§A‚‹´rŽ÷A^”\³KF‰E–[“àŽîᎂð”F‚ß‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—áB‘æ103‰ñ“ú–{zŠÂŠíŠw‰ï‹ß‹E’n•û‰ïA‘åãA2007”N6ŒŽ

 

Î”ò^lA‘“cTŽO: “–‰@‚É‚¨‚¯‚éTS-1‚¨‚æ‚ÑXeloda—¼ÜŽg—p—á‚ɂ‚¢‚Ä‚ÌŒŸ“¢B  ‘æ32‰ñ“ûŠà§˜b‰ï A‘åãA2007”N4ŒŽ

 

Î”ò^lA‘“cTŽOA’|“c‰ëŽiA^”\³KA“¿“c—R‹IŽqA‹g“c@ŒªAŽRèGÆA’Ò’‡—˜­Fp‘OŠw—Ö@Ç—á‚É‚¨‚¯‚é‰æ‘œŒŸ¸‚¨‚æ‚ѐj¶ŒŸ‚ð—p‚¢‚½Pathological CR—\‘z–@‚Ì—L—p«B‘æ15‰ñ“ûŠàŠw‰ï‘‰ïA‰¡•lA2007”N6ŒŽ

 

‘呺mºA“ú‰Y—Sˆê˜YA”ú±³Ž÷AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA‹{–{“ÖŽjA’†X³“ñA’Ò’‡—˜­FÏ‹É“IŽ¡—Âɂæ‚èpŒã5”N¶‘¶‚Ì“¾‚ç‚ꂽstage4bäXŠà‚Ì1—áB ‘æ38‰ñ “ú–{äX‘ŸŠw‰ï‘å‰ïA•Ÿ‰ªA2007”N6ŒŽ

 

‘呺mºA“¡’J˜a³A•½”ö‘fGAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FBulky N2ˆÝŠà‚ÍChRT‚̑ΏۂƂȂ肤‚é‚©\Ä”­Œ`Ž®‚©‚猩‚½ŒŸ“¢\B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

‘呺mºA‚Œ©N“ñA’ҍ]³“¿A‘å‹{‰p‘ׁAŽR‘º@‡AˆÀˆä¹‹`A”ú±³Ž÷A‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FŒŒ‹¹‚ðŒ_‹@‚É”­Œ©‚³‚êA‹¹–Œ–ü’…p‚ª’˜Œø‚µ‚½Gorham-Stout•a‚Ì1—áB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

¬ì‹v‹MA’†X³“ñA”ú±³Ž÷AÎ”ò^lA‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­A^”\³KA’|“c‰ëŽiFf’fAŽ¡—Âɓïa‚µ‚½äX”X–E«Žîᇂ̈ê—áB ‘æ38‰ñ “ú–{äX‘ŸŠw‰ï‘å‰ïA•Ÿ‰ªA2007”N6ŒŽ

 

¬ì‹v‹MA’†X³“ñA”ú±³Ž÷AÎ”ò^lAˆÀˆä¹‹`A‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­A^”\³KA’|“c‰ëŽiFf’f‚ÆŽ¡—Âɓïa‚µ‚½äX‚Ì‚¤–E«Žîᇂ̈ê—áB ‘æ19‰ñ “ú–{ŠÌ’_äXŠO‰ÈŠw‰ïEŠwpW‰ïA‰¡•lA2007”N6ŒŽ

 

¬ì‹v‹MA’†X³“ñA”è³Ž÷AÎ”ò^lA‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­A^”\³KA’|“c‰ëŽiFf’fAŽ¡—Âɓïa‚µ‚½äX”X–E«Žîᇂ̈ê—áA‘æ38‰ñ“ú–{äX‘ŸŠw‰ï‘å‰ïA•Ÿ‰ªA2007”N6ŒŽ

 

¬ì‹v‹MA‘“cTŽOAŽR‘º@‡A‘“chŽqAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­: “ûŠà‹ÇŠÄ”­•a‘ƒ‚Ö‚ÌMohs pasteŠO—p‚ÌŽŽ‚݁B ‘æ45‰ñ“ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

¬ì‹v‹MA‹{è“¹•FAˆÀˆä¹‹`A’r‰i‰ëˆêAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­Fãè–å’É‚Å”­Ç‚µ‚½ dermoid cyst ‚̈ê—áB ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

”ú±³Ž÷A‘呺mºA¼“c®OAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA‘ò‘º•q˜YA’†X³“ñA’Ò’‡—˜­FV‚½‚ȏpŒã‘nŠÇ—–@‚ÌŽŽ‚݁B ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

”ú±³Ž÷A‘呺mºA¼“c®OAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA‘ò‘º•q˜YA’†X³“ñA’Ò’‡—˜­FV‚½‚ȏpŒã‘nˆ’u–@‚̑Ó–«‚ÌŒŸ“¢|Á“łƖŋېێqŽg—p‚Ì”pŽ~B ‘æ32‰ñ “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïA“Œ‹žA2007”N6ŒŽ

 

”ú±³Ž÷A’†X³“ñAˆÀˆä¹‹`A‹{è“¹•FA’r‰i‰ëˆêA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­F‘å’°ŠàŠÌ“]ˆÚ‚ɑ΂·‚éFOLFOXp‘O‰»Šw—Ö@Œã‚̊̐؏œ—á‚ÌŒŸ“¢B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

”ú±³Ž÷A’†X³“ñA’ҍ]³“¿AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­F”ñØœEÄ”­’_“¹Šà‚ɑ΂·‚éTS]1^Gemcitabine•¹—p—Ö@‚ÌŽŽ‚݁B ‘æ43‰ñ “ú–{’_“¹Šw‰ïŠwpW‰ïi’_“¹jA“Œ‹žA2007”N9ŒŽ

 

”è³Ž÷A’†X³“ñA‹{–{“ÖŽjA’ҍ]³“¿AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA^”\³KAˆÉ‘q‹`OA’Ò’‡—˜­F‘å’°ŠàŠÌ“]ˆÚ‚ɑ΂·‚éFOLFOXp‘O‰»Šw—Ö@Œã‚̊̐؏œ—á‚ÌŒŸ“¢B‘æ69‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ

 

”ú±³Ž÷A’†X³“ñA‹{–{“ÖŽjA’ҍ]³“¿AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA^”\³KAˆÉ‘q‹`OA’Ò’‡—˜­F‘å’°ŠàŠÌ“]ˆÚ‚ɑ΂·‚éFOLFOXp‘O‰»Šw—Ö@Œã‚̊̐؏œ—á‚ÌŒŸ“¢B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

•Ð‰ª–¾”üA‘å–ì^ŽiAŒËˆä‰ë˜aA’†‘º´ŒáA•ˆäŽ¹AŠâ“cL–èA‰“ŽR—³–çA‘“cTŽO@“¿‰i‚¦‚èŽq: ƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`„i‚Ì‚½‚߂̃lƒbƒgƒ[ƒN\’zB@‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

ìè@ŒªA‚–ØŒiéA‘å‹´ŸŽqA—с@‹PŽqAŽ…ŽRŒõ–AÎ”ò^lA‘“cTŽOA’|“c‰ëŽiA^”\³K: p’†ƒZƒ“ƒ`ƒlƒ‹ƒŠƒ“ƒpßŒŸõ–@‚ɂ‚¢‚Ä‚ÌŒŸ“¢B ‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï A‰¡•lA2007”N6ŒŽ

 

‹v“cŒ´ˆè•vA‹ÊˆäésAã“cF•¶A’|“c‰ëŽiA^”\³KA¬¼‰pˆêFœE“î•”Žîᇂɂ¨‚¯‚ép’†v‘¬•a—f’f‚̈Ӌ`B‘æ40‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïœE“î•”ŽîᇊwpW‰ïAŽR—œA2007”N7ŒŽ

 

•ìK“TAùŽq@ŽO’ׯA²–ì@•AŽRŒû‘ñ—mA‹g‘ºŒ’ˆêAŽR–{¸ˆê˜YA•Ÿ“cŽ¡•FFˆÝŠàŽèp‚ÌRCT‚É‚¨‚¯‚éŽ{ÝŠÔ·‰ðÍ\JCOG9501•Œ¤‹†\B‘æ80‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ïA‰¡•lA2008”N2ŒŽ

 

¬à_Œ\—SA‘“cTŽOAÎ”ò^lAŒË‚Œ¦‘ãA“c’†“o”üA’†X³“ñA’Ò’‡—˜­FDocetaxel‚É‚æ‚é’܁E”畆áŠQ‚ª“úí¶Šˆ‚Ö‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚錟“¢B ‘æ15‰ñ “ú–{“ûŠàŠw‰ïŠwpW‰ïA‰¡•lA2007”N6ŒŽ

 

¬à_Œ\—SA’†X³“ñAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­F‘å’°ŠàˆÈŠO‚Ì“]ˆÚ«ŠÌŽîᇂɑ΂·‚éŠO‰È“IØœ‚ÌŒŸ“¢B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

¬à_Œ\—SA•½”ö‘fGA’ҍ]³“¿A‘å‹{‰p‘ׁAŽR‘º@‡AˆÀˆä¹‹`A”ú±³Ž÷A‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FˆÝŠàp‘Oƒ}[ƒLƒ“ƒOƒNƒŠƒbƒv‚ª’Ž‚‰Š‚ð—U”­‚µ‚½ˆê—áB ‘æ69 ‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ƒSƒƒXƒ‰ƒEƒ‰A‘å‹´ˆ¤”üA“Œ@LºA•Ÿˆä—¢‰ÀA•½“cŒöˆêA’†X³“ñA“ü‘º’B˜YFPossible role of ASGPR in the development of liver metastasis from gastric cancerB ‘æ66‰ñ “ú–{ŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N10ŒŽ

 

¼“ƒ‘ñ˜YA•½”ö‘fGA“¡’J˜a³AŽR‘º@‡A’ҍ]³“¿AˆÀˆä¹‹`A‘“cTŽOA‘å‹{‰p‘ׁA‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FA‚Œ©N“ñAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FH“¹ŠàT1Ç—á‚É‚¨‚¯‚éd•¡Šà”­¶‚ÌŒŸ“¢B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

²“¡Œ³FA•Ÿ“c‘ŽqA‚‹´@“OAŒ´“c‘׋KA“Œ“c@ÍAˆÀ‰i@–LA‰ª@¹ŽŸA’|“c‰ëŽiA^”\³KF¸‘ƒMyxoma‚Ì1—áB‘æ196‰ñ“ú–{”å”AŠí‰ÈŠw‰ïŠÖ¼’n•û‰ïA‹ž“sA2007”N9ŒŽ

 

‘ò‘º•q˜YAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F‚»‚¯‚¢ƒwƒ‹ƒjƒA‚ɑ΂·‚é4Ží—Þ‚Ì‘gD‘ã—p‡¬‘@ˆÛ•z<ƒƒbƒVƒ…>“K—p‚ɂ‚¢‚āB ‘æ107 ‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

Žl•û•¶ŽqA‘“cTŽOAŒË‚Œ¦‘ãA“c’†“o”üA_Š_r“ñAˆäŠÖç—TA¼—Ñ”Ž”üAˆ¢“ìßŽqAã–ì—T”VA’†ŽR‹MŠ°: “û‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚éƒhƒZƒ^ƒLƒZƒ‹Ž{sŽž‚ÌFrozenGrove(FG)‚Ì—LŒø«‚ÉŠÖ‚·‚é•]‰¿B‘æ45‰ñ“ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

—é–؁@—æA’r“c³FAš£–썎Ž÷A–x@‰ë•qA’|­ˆÉ’m˜NAŽR–{_•¶A‘åA‰ë”VA’†X³“ñAŠÖ–{vŽkA¶‹ßŒ«lA–å“cŽçlFÁ‰»ŠíŠàpŒã‚̍R‹ÃŒÅÜ“Š—^‚̋ÌŌnƒ}[ƒJ[‚ɉe‹¿‚ÉŠÖ‚·‚錟“¢B ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

‚“cWGA“¡’J˜a³A•½”ö‘fGAŽR‘º@‡A’ҍ]³“¿AˆÀˆä¹‹`A‘“cTŽOA‘å‹{‰p‘ׁA‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FA‚Œ©N“ñAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F•¬–呤ˆÝØœpŒã‚̍Čš–@‚Ì”äŠrF‹ó’°”XŠÔ’upvsH“¹ŽcˆÝ•«‡pB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

‚“cWGA’Ò’‡—˜­A•½”ö‘fGA“¡’J˜a³A’ҍ]³“¿AˆÀˆä¹‹`A‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñF“–‰@‚ł̈݊àpŒãpƒNƒŠƒjƒJƒ‹ƒpƒXB ‘æ80‰ñ “ú–{ˆÝŠàŠw‰ï‘‰ïA‰¡•lA2008”N2ŒŽ

 

‚Œ©N“ñA‘O“c@ƒA‰ªŒ©ŽŸ˜YA”ö“cˆê”VA“ŒŽR¹•FAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’†X³“ñA‘ò‘º•q˜YA’Ò’‡—˜­AŽ™‹Ê@Œ›F”xŠà‚ɑ΂·‚é”x‘S“Ep‚̍¶‰E•ÊpŒã¬Ñ‚ÉŠÖ‚·‚錟“¢B‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

•“c@—TA’†X³“ñA‹k‚M‹`A‹{–{“ÖŽjAŠÛ‹´@”ɁAŽí‘º‹§OA–kì@“§A‰i–ì_ºA”~‰º_ŽiA“°–ìŒbŽOA–å“cŽçlFisäXŠàŽ•ž‚Ö‚ÌŽ¡—Ð헪iisäXŠà‚ɑ΂·‚é@Gemcitabine ‚ƉÁ‘¬‘½•ªŠ„ÆŽË–@‚ð—p‚¢‚½“¯Žž•úŽËü‰»Šw—Ö@B ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

•“c@—TA’†X³“ñA‹{–{“ÖŽjA¬—яȌáAŠÛ‹´@”ɁA–kì@“§A‰i–ì_ºA”~‰º_ŽiA“°–ìŒbŽOA–å“cŽçlFStage‡Wa‹ÇŠisäXŠà‚ɑ΂·‚鎡—Ð헪B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

“c’†“o”üA‘“cTŽOAŒË‚Œ¦‘ãAã–ì—T”VAÎ”ò^lA’Ò’‡—˜­: “û‘Bƒ`[ƒ€‚É‚¨‚¯‚邪‚ñŠÅŒìê–åŠÅŒìŽt‚Ì–ðŠ„‚Æ‰Û‘èB‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

“c’†“o”üA‘“cTŽOAŒË‚Œ¦‘ãAã–ì—T”VAÎ”ò^lA’†ŽR‹MŠ°F“ûŠàŠ³ŽÒ‚É‚¨‚¯‚éƒhƒZƒ^ƒLƒZƒ‹“Š—^Žž‚ÌFrozen Glove‚Ì—LŒø«B‘æ6‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ïA•Ÿ‰ªA2008”N3ŒŽ

 

“c’†^‹IA‘“cTŽOAˆ¢“ìŒh¶A¼‘º—ߊìA’JŒû‰pŽ÷AŠC£”ŽŽjA‘å–ì^ŽiAŒõŽR¹ŽìA“c’†˜a•v: “]ˆÚ«“ûŠà‚ɑ΂·‚éƒ[ƒ[ƒ_‚ƃGƒ“ƒhƒLƒTƒ“•¹—p‘æ2—Տ°ŽŽŒ±i’†ŠÔ•ñjB ‘æ45‰ñ“ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ 

 

’Ò’‡—˜­A•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’r‰i‰ëˆêA‹{è“¹•FAˆÀˆä¹‹`A’†X³“ñA”ú±³Ž÷AŒÃ‰Í@—mFÁ‰»Ší‚ª‚ñŽèp‘O–Ɖu‘‹­‰h—{Ü‚ÌŒø‰Ê‚ƗՏ°ŽŽŒ±B ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

’Ò’‡—˜­A“¡’J˜a³A•½”ö‘fGAŽO“ˆGsA‚Œ©N“ñA‹{è“¹•FA’r‰i‰ëˆêAˆÀˆä¹‹`A”ú±³Ž÷A’†X³“ñFØœ‰Â”\isˆÝŠà‚ɑ΂·‚鎡—Ð헪\p‘O‰»Šw—Ö@‚̈Ӌ`B ‘æ45‰ñ “ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

“¿“c—R‹IŽqA‘“cTŽOA’|“c‰ëŽiA‹g“c@ŒªA‘½ªˆä@’q‹IAÎ”ò^lA^”\³KA×–Ø‘ñ–ìFMRI‚É‚æ‚é“ûŠàp‘O‰»Šw—Ö@ŒãpCR—\‘ª‚ÌŒŸ“¢B‘æ65‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠwpW‰ï´˜^WA2007”N4ŒŽ

 

“¿“c—R‹IŽqAŒIŽRŒ[ŽqA’†–{@“āA‰Í‡”ü²A‰H“cFŽiAš •x—TŽ÷A–û’JŒ’ŽiA›Á@G”üA‘“cTŽOA’|“c‰ëŽiFBI-RADS MRI‚ÉŠî‚¢‚½“û“ªˆÙí•ª”åÇ—á‚ÌŒŸ“¢B‘æ17‰ñ“ú–{“ûŠà‰æ‘œŒ¤‹†‰ïA“Œ‹žA2008”N2ŒŽ

 

’†•½@LA’†X³“ñA™–{Œ\ŽiA•y“c®—TA‚’Ë—YˆêA’ҍ]³“¿A‰ªŒ©ŽŸ˜YA’|­ˆÉ’m˜NAŠÛ‹´@”ɁA‹{–{“ÖŽjA•“c@—TA‰i–ì—TºA“°–ìŒbŽOA”~‰º_ŽiA¶‹ßŒ«lA–å“cŽçlFäXŠà‚É‚¨‚¯‚éGemcitabine‘ϐ«‹@˜‚ÌŠî‘b“IE—Տ°“IŒŸ“¢B‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åã A2007”N4ŒŽ

 

’†X³“ñA”ú±³Ž÷A•“c@—TAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGAŽO“ˆGsA“¡’J˜a³A’Ò’‡—˜­F”ñZ«‚¨‚æ‚Ñ”÷¬Z«äXŠÇ“à“û“ª”S‰t«Žîᇂ̍Ĕ­—á‚ÌŒŸ“¢B ‘æ38‰ñ “ú–{äX‘ŸŠw‰ï‘å‰ïA•Ÿ‰ªA2007”N6ŒŽ

 

’†X³“ñA”ú±³Ž÷AˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA•½”ö‘fGA“¡’J˜a³A’Ò’‡—˜­FäXŠà‚É‚¨‚¯‚é“œ“]ˆÚy‘fGalNAcT3‚Ì”­Œ»‚̗Տ°“IˆÓ‹`B ‘æ38‰ñ “ú–{äX‘ŸŠw‰ï‘å‰ïA•Ÿ‰ªA2007”N6ŒŽ

 

’†X³“ñA’ҍ]³“¿A”ú±³Ž÷AˆÀˆä¹‹`A’r‰i‰ëˆêA•½”ö‘fGA‹{è“¹•FA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­FHuman Equilibrative Nucleoside Transporter 1,as a Predic of 5-Fluorouracil Resistance in Human Pancreatic CancerB ‘æ66‰ñ “ú–{ŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N10ŒŽ

 

’†ŽR‹MŠ°A‘“cTŽOFTS-1/Trastuzumab•¹—p—Ö@-’˜Œø—á‚Ì•ñ‚Æ‘æI-II‘ŠŽŽŒ±‚̏Љî- Kinki Breast Cancer Study Group (KBCSG)B‘æ32‰ñ“ûŠà§˜b‰ïA‘åãA2007”N4ŒŽ

 

’†ŽR‹MŠ°A’†ŽR‹MŠ°A‘“cTŽOA@_Š_r“ñAˆ¢“ìßŽqAˆäŠÖç—TA¼—щ·”üA“¡–ì”ü²ŽqA“¡ˆäç‰êj@Î”ò^l@A“c’†“o”üAŒË‚Œ¦‘ãAã–ì—T”VA@—´“c^s: ƒhƒZƒ^ƒLƒZƒ‹“Š—^Žž‚É‚¨‚¯‚éFrozen Glove‚Ì—L—p«‚ÉŠÖ‚·‚é—Տ°“I•]‰¿B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

¼“c®OA’r‰i‰ëˆêAˆÀˆä¹‹`A‹{è“¹•FAŽO“ˆGsAÎ”ò^lA‘“cTŽOA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F”]Žº|• oA@˜’Ł|• oƒhƒŒƒi[ƒWƒ`ƒ…[ƒu—¯’u’†‘å’°ŠàŽèpÇ—á3—á‚ÌŒŸ“¢B ‘æ32‰ñ “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïA“Œ‹žA2007”N6ŒŽ

 

¼“c®OA“¡’J˜a³A•½”ö‘fGAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FH“¹ZˆÝŠàÇ—á‚̍Ĕ­Œ`Ž®‚ÉŠÖ‚·‚錟“¢B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

¼“c®OAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FSóŒ‹’° cellular schwannoma ‚̈ê—áB ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

¼“c®OA’r‰i‰ëˆêAŽR‘º@‡A’ҍ]³“¿A‘å‹{‰p‘ׁAˆÀˆä¹‹`A‘“cTŽOA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F”]Žº|• oA˜’Ł|• oƒhƒŒƒi[ƒWƒ`ƒ…[ƒu—¯’u’†Œ‹’°Šà‚ւ̑ΉžB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

à_‰ª@„A’†‘º´ŒáA@‘“cTŽOA@Šâ“cL–è@A•ˆäŽ¹A•Z¹ŽjA’Óc@‹ÏAHŽR@‘¾AŒËˆä‰ë˜a: JBCRG02:Œ´”­«“ûŠà‚É‚æ‚éFEC100 followed by Docetaxel 100‚É‚æ‚ép‘O‰»Šw—Ö@B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

•½”ö‘fGA“¡’J˜a³A’†X³“ñA‘ò‘º•q˜YAŽO“ˆGsA‚Œ©N“ñA‹{è“¹•FA’r‰i‰ëˆêA‘“cTŽOA”ú±³Ž÷AˆÀˆä¹‹`AÎ”ò^lA’Ò’‡—˜­FˆÝŠàpŒã‘ŠúŒoŒûÛŽæ‚ÉŠÖ‚·‚é‘OŒü‚«—Տ°ŽŽŒ±Œ‹‰Ê‚ƁA‚»‚ê‚ÉŠî‚­ƒNƒŠƒjƒJƒ‹ƒpƒX‚Ì•Ï‘JB ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

•½”ö‘fGA’Ò’‡—˜­A“¡’J˜a³A’†X³“ñAŽO“ˆGsA‚Œ©N“ñA‹{è“¹•FA’r‰i‰ëˆêA”ú±³Ž÷AˆÀˆä¹‹`F—H–呤ˆÝØœŒãRoux-en-YÄŒš‚̍H•vƒŠíŠB•«‡Žg—pƒÏR-YÄŒš–@„B ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

•½”ö‘fGA’Ò’‡—˜­A“¡’J˜a³A•ìK“TA’†X³“ñAŽO“ˆGsA‹{è“¹•FA’r‰i‰ëˆêAˆÀˆä¹‹`A’ҍ]³“¿A‹{–{“ÖŽjF\ˆÝŠà—H–呤ˆÝØœŒãR-YÇŒóŒQ‚Í—\–h‚Å‚«‚é‚Ì‚©H\(‘OŒü—Տ°ŽŽŒ±‚ÌŒ‹‰Ê‚©‚ç)B ‘æ80‰ñ “ú–{ˆÝŠàŠw‰ï‘‰ïA‰¡•lA2008”N2ŒŽ

 

“¡’J˜a³A’Ò’‡—˜­AŽRèGÆA•½”ö‘fGAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FA‚Œ©N“ñAŽO“ˆGsA’†X³“ñFˆÝŠàÄ”­Ç—á‚É‚¨‚¯‚é2ŽŸ/3ŽŸŽ¡—ÂƂµ‚Ẵtƒb‰»ƒsƒŠƒ~ƒWƒ“/TXT•¹—p‰»Šw•úŽËü—Ö@B ‘æ45‰ñ “ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

“¡’J˜a³A‹{Š_”Ž“¹A•½”ö‘fGA’ҍ]³“¿AˆÀˆä¹‹`A‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F”ñŽ¡–üˆÝŠà‚ɑ΂·‚鎡—Ð헪|ˆÝØœ‚̈Ӌ`‚ƃ^ƒCƒ~ƒ“ƒO|B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ŒÃì‡NA‚’Ë—YˆêA@h@‰h¬A@‘“cTŽOA@ŒõŽR¹ŽìA@¬¼@–LA¼ìG•¶A‹{“àŒ[•ãA@‘O‰Y‹`ŽsA@ŽR–{@m@A‹{‰ºŸA‘åÎ‰ë—mA–쑺@F@AŽR’†‰pŽ¡A@æ“c@Œ÷A@–k“c¹”V: •ÂŒoŒã‘Šú“ûŠàiTƒ3cm@ANO)‚ɑ΂·‚éãüâ|ƒŠƒ“ƒpßŠs´‚Æ”ñŠs´‚Ì”äŠrŽÀŒ±B‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

‘“cTŽO: uŒoŒû5-FUŒn@RŠàÜ‚ÌŒ»ó‚Æ“W–]v “–”Ԑ¢˜blB  ‘æ32‰ñ“ûŠà§˜b‰ïA‘åãA2007”N4ŒŽ

 

‘“cTŽOA’†ŽR‹MŠ°AÎ”ò^lAX–{@‘ìA¼•À“W‹PA’|“c‰ëŽi: HER2—z«“û‚ª‚ñ‚ɑ΂·‚éV‚µ‚¢Ž¡—Ð헪FFEC@followed by weekly Paclitaxel & Trastuzumab’€ŽŸp‘O‰»Šw—Ö@‚ÌŽŽ‚݁B‘æ19‰ñ“ú–{“à•ª”åŠO‰ÈŠw‰ï‘‰ï A–¼ŒÃ‰®A2007”N5ŒŽ

 

‘“cTŽOAÎ”ò^l@“c’†“o”üAŒË‚Œ¦‘ãAŽl•û•¶ŽqA’Ò’‡—˜­: •ÂŒo‘O“ûŠà‚É‚¨‚¯‚鉻Šw—Ö@—U”­–³ŒŽŒoiCRA)‚Æ—‘‘ƒ‹@”\•ÛŒì‚̍H•vB‘æ15‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ïA‰¡•lA2007”N6ŒŽ

 

‘“cTŽOAÎ”ò^lAŽR“c^”üA’|“c‰ëŽiA“¿“c—R‹IŽqAŽR‘º@‡A‘“chŽqA^”\³KA’Ò’‡—˜­F“û“ªˆÙí•ª”åÇ—á‚ɑ΂·‚éÔŠOŠÏŽ@ƒJƒƒ‰ƒVƒXƒeƒ€(PDE)‚ð—p‚¢‚½MicrodochectomyB‘æ45‰ñ“ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

‘“cTŽOAX–{‘ìA’†ŽR‹MŠ°A¼•À“W‹PA–쑺FA’Ë–{•¶‰¹A‘å‹´–õ—YA“cŒû“N–çA’Ò’‡—˜­F“ú–{l“ûŠà‚É‚¨‚¯‚éTC(Docetaxel-Cyclophosphamide)—Ö@‚ÌŒŸ“¢B‘æ6‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ïA•Ÿ‰ªA2008”N3ŒŽ

 

‘“chŽqA‘“cTŽOAŽR‘º@‡A’ҍ]³“¿A‘å‹{‰p‘ׁAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fOA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­: Aromatase Inhibitor(AI)ÜŽg—p’†‚ÉŒŽŒoÄŠJ‚ð”F‚ß‚½“ûŠàÇ—áB ‘æ69‰ñ@“ú–{—Տ°ŠO‰ÈŠw‰ïA‰¡•lA2007”N11ŒŽ

 

¼•À“W‹PA—´“c^sA’†ŽR‹MŠ°A_Š_r“ñA¼•q•vA‘òˆäƒ†ƒJA‘“cTŽOA“¿“c—R‹IŽqA’r–{”ü“ÞŽqAŽÂŒ´”͏[AŒÃÈ‰ÃˆêF’nˆæŠJÃŒ^ƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒB•×‹­‰ï‚̈Ӌ`‚ɂ‚¢‚Ä-3‰ñ‚̓ljeŽŽŒ±‚ð’Ê‚µ‚āB‘æ17‰ñ“ú–{“ûŠàŒŸfŠw‰ï‘‰ïA ‰¡•lA2007”N11ŒŽ

 

ŽO–Ø—Fˆê˜NA’Ò’‡—˜­A’ҍ]³“¿A‘å‹{‰p‘ׁAŽR‘º@‡AˆÀˆä¹‹`A”ú±³Ž÷A‘“cTŽOA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñF\“ñŽw’°GIST‚Ì6—áB ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ŽO–Ø—Fˆê˜NA“¡’J˜a³A’ҍ]³“¿AˆÀˆä¹‹`A‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F“§ÍŠ³ŽÒ‚É‚¨‚¯‚éˆÝŠàŽèp‚Ì–â‘è“_‚Æ‚»‚̑΍ôB ‘æ80‰ñ “ú–{ˆÝŠàŠw‰ï‘‰ïA‰¡•lA2008”N2ŒŽ

 

‹{Š_”Ž“¹A“¡’J˜a³A•½”ö‘fGAˆÀˆä¹‹`A”ú±³Ž÷A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FisˆÝŠà‚ւ̃Aƒvƒ[ƒ`F‚ǂ̂悤‚ȏǗá‚ɏp‘O• o‹¾ŒŸ¸‚ðs‚¦‚ÎŒø—¦“I‚©H ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

‹{è“¹•FAŽO“ˆGsA’r‰i‰ëˆêAˆÀˆä¹‹`A•½”ö‘fGA“¡’J˜a³A”ú±³Ž÷A’†X³“ñA‚Œ©N“ñA‘ò‘º•q˜YAÎ”ò^lA‘“cTŽOA’Ò’‡—˜­F‹’“_•a‰@‚É‚¨‚¯‚é‚g‚h‚u—z«ŽÒãè–厾Š³‚ÌŽ¡—ÁB ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

‹{è“¹•FAŽO“ˆGsAˆÀˆä¹‹`A•½”ö‘fGA“¡’J˜a³A”ú±³Ž÷A’†X³“ñA‚Œ©N“ñA’Ò’‡—˜­A’r‰i‰ëˆêFuãè–剷‘¶Žèp‚Å–ž‘«‚·‚é‚Ì‚Í’N‚©HvŒoãè–呤’[•«‡p‚Ì’·ŠúŒo‰ßpŒãƒAƒ“ƒP[ƒgŒ‹‰ÊB ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

‹{è“¹•FAŽO“ˆGsA’r‰i‰ëˆêAˆÀˆä¹‹`A”ú±³Ž÷A•½”ö‘fGA“¡’J˜a³A‚Œ©N“ñA‘“cTŽOA’†X³“ñA’Ò’‡—˜­FRHIV—Ö@•¹—p‰»Šw•úŽËü—Ö@‚ðŽ{s‚µCR‚𓾂½HIV—z«ãè–åŠÇŠà‚Ì1—áB ‘æ45‰ñ “ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

‹{è“¹•FAŽO“ˆGsA’r‰i‰ëˆêAˆÀˆä¹‹`A’†X³“ñA’Ò’‡—˜­F‘SŽüፍ­«ãè–å‹·ó‚É‚½‚¢‚·‚éãè–åŒ`¬pB ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

‹{–{“ÖŽjA“°–ìŒbŽOAà_@’¼Ž÷A–ì“c„LA¬—яȌáAŠÛ‹´@”ɁA•“c@—TA‰i–ì_ºA”~‰º_ŽiA–å“cŽçlF’†‰º•”’_ŠÇŠà‚ɑ΂·‚éŽèppŽ®‚ÌŒŸ“¢B‘æ107‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïA‘åãA2007”N4ŒŽ

 

‹{–{“ÖŽjA“°–ìŒbŽOAà_@’¼Ž÷A–ì“c„LA¬—яȌáAŠÛ‹´@”ɁA•“c@—TA‰i–ì_ºA”~‰º_ŽiA–å“cŽçlFŠÌ–å•”’_ŠÇŠà‚ɑ΂·‚鎡—Õûj‚ÌŒŸ“¢B‘æ19‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïEŠwpW‰ïA‰¡•lA2007”N6ŒŽ

 

‹{–{“ÖŽjA“°–ìŒbŽOA¬—яȌáAŠÛ‹´@”ɁA•“c@—TAŽí‘º‹§OA‰i–ì_ºA–kì@“§A”~‰º_ŽiA–å“cŽçlF’_“¹Šà‚ɑ΂·‚éŠg‘åŽèp‚Ì“K‰ž‚ÉŠÖ‚·‚錟“¢B‘æ62‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

‹{–{“ÖŽjA´…ŽOA”~‰º_ŽiA¬—Ñ“N˜YA–å“cŽçlF‘½Ž{Ý‹¤“¯ƒT[ƒxƒCƒ‰ƒ“ƒX‚ÉŠî‚­Žèp•”ˆÊŠ´õ—\–h‘΍ô‚ÉŠÖ‚·‚錟“¢B‘æ69‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ

 

ˆÀˆä¹‹`A’r“c³FA”ú±³Ž÷A’†X³“ñA’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA“¡’J˜a³AŽO“ˆGsA’Ò’‡—˜­FŠÌd•ÏEäB‹@”\˜´iÇŠ³ŽÒ‚É‚¨‚¯‚é• o‹«‰ºäB‘Ÿ“EopB ‘æ62 ‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

ˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F’¼’°Šà‹ÇŠÄ”­Ç—á‚ÌŒŸ“¢B‘æ45‰ñ “ú–{ŠàŽ¡—Êw‰ï‘‰ïA‹ž“sA2007”N10ŒŽ

 

ˆÀˆä¹‹`A’r“c³FAŠÖ–{vŽkA”ú±³Ž÷A’ҍ]³“¿A’†X³“ñA’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA•½”ö‘fGA“¡’J˜a³A’Ò’‡—˜­FHand-Assisted Surgery Using Intra-abdominal device(HASUI)‚É‚æ‚é• o‹¾‰ºäB‘Ÿ“EopB ‘æ20‰ñ “ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ïAå‘äA2007”N11ŒŽ

 

ˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FAŽO“ˆGsA’ҍ]³“¿A”ú±³Ž÷AŽR‘º@‡A‘“cTŽOA‘å‹{‰p‘ׁA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA’Ò’‡—˜­F‘å’°ŠàŽèpŠ³ŽÒ‚É‚¨‚¯‚鍇¬‹zŽû«–ü’…–hŽ~ÜiƒZƒvƒ‰ƒtƒBƒ‹ƒ€j‚Ì—v–]“x’²¸B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ˆÀˆä¹‹`A‹{è“¹•FA’r‰i‰ëˆêAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F’¼’°’E‚ɑ΂·‚éŒo• “IStapling RectopexyB ‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

ŽR“c^”üA’r‰i‰ëˆêAˆÀˆä¹‹`A‹{è“¹•FAŽO“ˆGsAÎ”ò^lA‘“cTŽOA”ú±³Ž÷A•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³A’†X³“ñA‘ò‘º•q˜YA’Ò’‡—˜­FŒ´”­«’Ž‚ˆ««Žîá‡10—á‚̗Տ°•a—Šw“IŒŸ“¢B ‘æ107‰ñ “ú–{ŠO‰ÈŠw‰ïA‘åãA2007”N4ŒŽ

 

ŽR“c^”üA‹{è“¹•FAˆÀˆä¹‹`A’r‰i‰ëˆêAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­FHIV—z«ëŒ\ƒRƒ“ƒWƒ[ƒ€[–žŽ¤á‘‚̈ê—áB‘æ62‰ñ “ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïA“Œ‹žA2007”N11ŒŽ

 

ŽR“c^”üA“¡’J˜a³A•½”ö‘fGAŽR‘º@‡A’ҍ]³“¿AˆÀˆä¹‹`A‘“cTŽOA‘å‹{‰p‘ׁA‹{–{“ÖŽjA’r‰i‰ëˆêA‹{è“¹•FA‚Œ©N“ñAŽO“ˆGsA’†X³“ñA’Ò’‡—˜­F“–‰È‚É‚¨‚¯‚éŠÉ˜aŽèp‚ÌŒŸ“¢B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

ŽR“c^”üA‹{–{“ÖŽjA’ҍ]³“¿A’†X³“ñA’Ò’‡—˜­F‘ŠúˆÝŠà‚̐¸¸’†‚É‹ô‘R”­Œ©‚³‚ꂽ\“ñŽw’°GIST‚Ì1—áB ‘æ182‰ñ ‹ß‹EŠO‰ÈŠw‰ïA‘åãA2007”N12ŒŽ

 

‹g“c@ŒªA”\¨—²”VAŽRèGÆA‹g“c›¨—YA’Mˆä—˜–¾AŽOã–ƒ—¢A•’†@³A‘åZ@—²A“¿“c—R‹IŽqAŒIŽRŒ[ŽqA’|“c‰ëŽiA‘“cTŽOF“û–[‰·‘¶pŒã‚̍‚ü—Ê—¦‘gD“àÆŽË’P“ƗÖ@B“ú–{•úŽËüŽîᇊw‰ï-¬üŒ¹Ž¡—Õ”‰ï‘æ9‰ñŒ¤‹†‰ïAŒQ”nA2007”N6ŒŽ

 

“n粁@‘åA‰ª–{‰l—¢ŽqAåb“c”üŽÑA’Å–Ø‘nˆêAùì@~A–ŒhŽj˜YA’JŒû’qGA•x¬LŽŸ˜YA–q]r—YAŽR–{‘P•FAã•½’©ŽqA^”\³KA”’ã‘ô–FHIV-1Š´õÇ‚É‚¨‚¯‚錌´ƒTƒCƒgƒJƒCƒ“’l‚̉ðÍB‘æ21‰ñ“ú–{ƒGƒCƒYŠw‰ïŠwpW‰ï‘‰ïAL“‡A2007”N11ŒŽ

 

iÀ’·j’†X³“ñF“]ˆÚˆâ“`Žq-2B‘æ16‰ñ “ú–{‚ª‚ñ“]ˆÚŠw‰ï‘‰ïA•xŽRA2007”N7ŒŽ

 

iÀ’·j’†X³“ñF äXEŽîᇁB ‘æ62‰ñ “ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwp‘‰ïA“Œ‹žA2007”N7ŒŽ

 

iÀ’·j’†X³“ñFäX14B ‘æ69 ‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

iÀ’·j’†X³“ñFäX‘ŸE\“ñŽw’°‡TB ‘æ182‰ñ ‹ß‹EŠO‰ÈŠw‰ïA‘åãA2007”N12ŒŽ

 

iŽi‰ïj’†X³“ñFŠO—ˆ‰»Šw—Ö@1B ‘æ69‰ñ “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïA‰¡•lA2007”N11ŒŽ]12ŒŽ

 

iÀ’·j‘“cTŽO: Œû‰‰13@‹³ˆçB “ú–{“û‚ª‚ñŒŸfŠw‰ï‘‰ï A‰¡•lA 2007”N11ŒŽ

 

B-5

ã“cF•¶F“úíf—Âɂ¨‚¯‚鍜E“î•”Žîᇐf’f‚Ì‚½‚߂̃|ƒCƒ“ƒgB‘æ1‰ñ‘åã`®Œ`ŠO‰È•×‹­‰ïA‘åãA2007”N6ŒŽ

 

ã“cF•¶FœE“î•”ˆ««Žîᇂɑ΂·‚銳Žˆ‰·‘¶—Ö@‚Ì•Ï‘J‚Ɛi•àB‘æ7‰ñ‹ž“s•{—§ˆã‘åƒTƒ‹ƒRƒNƒ‰ƒu(“÷ŽîŒ¤‹†‰ï)“Á•Êu‰‰A‹ž“sA2007”N9ŒŽ

 

ã“cF•¶FœE“î•”ˆ««Žîᇂɑ΂·‚銳Žˆ‰·‘¶—Ö@‚̐i•àBŒF–{®Œ`ŠO‰È‹Î–±ˆã‰ïŠwpu‰‰‰ï “Á•Êu‰‰AŒF–{A2008”N2ŒŽ

 

‘“cTŽO,: 2007 St Gallen“û‚ª‚ñƒJƒ“ƒtƒ@ƒŒƒ“ƒXƒŒƒrƒ…[B‚`‚hŽž‘ã‚̏pŒã•â•“à•ª”å—Ö@A‘åãA2007”N4ŒŽ 

 

‘“cTŽO: 2007 St.Gallen “û‚ª‚ñƒVƒ“ƒ|ƒWƒEƒ€ƒŒƒrƒ…[B  ‚ª‚ñŽ¡—Õ׋­‰ïA‘åãA2007”N5ŒŽ

 

‘“cTŽO: •ÂŒoŒã“à•ª”å—Ö@@-‚`‚hÜ‚ƍœŒ’NB ”õŒã“ûŠà§˜b‰ï AL“‡A2007”N5ŒŽ

 

‘“cTŽO: •ÂŒo‘O“ûŠàŽ¡—Â̌»ó‚Æ“W–]B  “ûŠà‚s‚uƒVƒ“ƒ|ƒWƒEƒ€A‘åãA2007”N6ŒŽ

 

‘“cTŽO: •ÂŒoŒã“ûŠà‚ɑ΂·‚éRƒAƒƒ}ƒ^[ƒ[—Ö@‚ÆBone HealthB“Þ—Ç“ûŠà§˜b‰ïA“ޗǁA2007”N7ŒŽ

 

‘“cTŽO: “ûŠàŽ¡—ÃASCO UPDATEB ‹ž“sABCMƒTƒ}[ƒLƒƒƒ“ƒvA‹ž“sA2007”N7ŒŽ

 

‘“cTŽO: isEÄ”­“ûŠà‚̍ŋ߂̎¡—ÂɊւµ‚āBThe 8th Breast Cancer Academia AL“‡A2007”N8ŒŽ

 

‘“cTŽO: “ûŠàƒzƒ‹ƒ‚ƒ“—Ö@‚̍ŐV’mŒ©‚ÆBone HealthB”ö’£–k•”“ûŠà§˜b‰ïA–¼ŒÃ‰®A2007”N11ŒŽ

 

‘“cTŽO: “ûŠàf—Â̂±‚ê‚©‚ç@2007-2008B ‘åã“ûŠà§˜b‰ïA‘åã A2007”N 11ŒŽ

 

‘“cTŽO: “ûŠàŽ¡—Â̍őOü‚Æ“ûŠàŒŸf|¸–§ŒŸ¸‹@ŠÖ‚©‚ç‚Ý‚½“ûŠàŒŸf‚Ì“W–]B ‘æ21‰ñ¼‹{ƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒB[Œ¤‹†‰ïA¼‹{A2007”N12ŒŽ

 

‘“cTŽOFSABCS2007•ñ@Chemoteraphy Topics‚̍u‰‰B‘æ‚P‰ñKansai Breast Cancer Expert ConferenceA‘åãA2008”N1ŒŽ

 

‘“cTŽOF“û‚ª‚ñ‚ɑ΂·‚éÅV‚̉»Šw—Ö@‚ÌŒ»ó‚ɂ‚¢‚āB@ƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹|“û‘Bf—Ã2008|A‘åãA2008”N1ŒŽ

 

‘“cTŽOF“û‚ª‚ñ‚ɑ΂·‚éÅV‚̉»Šw—Ö@‚ÌŒ»ó‚̍u‰‰BOsaka Breast Cancer Round Table DiscussionA‘åãA2008”N2ŒŽ

 

‘“cTŽOF“û‚ª‚ñ‚̏p‘OŽ¡—Âɑ΂·‚éÅV‚Ì’mŒ©‚̍u‰‰BŽF–€“ûŠà§˜b‰ïAŽ­Ž™“‡A2008”N2ŒŽ

 

‘“chŽqA‘“cTŽOAŽR‘º@‡A’ҍ]³“¿A‘å‹{‰p‘ׁAˆÀˆä¹‹`A’r‰i‰ëˆêA‹{è“¹•FA•½”ö‘fGA‚Œ©N“ñA“¡’J˜a³AŽO“ˆGsA’†X³“ñA’Ò’‡—˜­: Aromatase Inhibitor(AI)ÜŽg—p’†‚ÉŒŽŒoÄŠJ‚ð”F‚ß‚½•ÂŒoŒã“ûŠàÇ—áB ‘æ5‰ñ“ú–{“ûŠàŠw‰ï‹ß‹E’n•û‰ïA‘åãA2007”N12ŒŽ 

 

‘“chŽqA‘“cTŽOAŽR‘º@‡A’†X³“ñA’Ò’‡—˜­: Aromatase Inhibitor(AI)ÜŽg—p’†‚ÉŒŽŒoÄŠJ‚ð”F‚ß‚½•ÂŒoŒã“ûŠàÇ—áB ‘æ5‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ïA‰¡•lA2007”N12ŒŽ

 

ŽR‘º@‡A@‘“cTŽO@A‘“chŽqA@’†X³“ñA@’Ò’‡—˜­: ’·Šú•ª”厡—Ã’†‚̏d“Ä‚È“]ˆÚ«“ûŠà‚ɑ΂µƒn[ƒZƒvƒ`ƒ“‚ƃpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚Á‚ж–½Šë‹@‚ð’E‚µ‚½ˆê—áB ‘æ15‰ñ“ú–{“ûŠàŠw‰ï‹ß‹E’n•û‰ïA‘åãA2007”N12ŒŽ 

 

iÀ’·jˆê”ʉ‰‘è@‘“cTŽOFƒzƒ‹ƒ‚ƒ“—Ö@‚ƍœ‘e‚µ‚傤ÇBBreast Cancer Clinical SeminarA‘åãA2008”N1ŒŽ

 

iÀ’·j‘“cTŽO: ‚`‚PÜŽ¡—Âɂ¨‚¯‚鍡Œã‚Ì“W–]‚ðl‚¦‚éB The 1st@KYOTO Oncology@SCHOOL,KOSA‹ž“sA2007”N11ŒŽ

 

iÀ’·j‘“cTŽO: AIÜ‚ƍœŒ’NB‘æ8‰ñ“ûŠàÅVî•ñƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX[ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[ A‘åãA2007”N7ŒŽ

 

iÀ’·j‘“cTŽO: ‘æ2•”@Ž¡—Âɂ‚¢‚āB‘æ2‰ñKinki Breast Cancer Frontier MeetingA‘åãA2007”N3ŒŽ 

 

iÀ’·j‘“cTŽO:F“Á•Êu‰‰‚Æ‘‡“¢˜_B‘æ11‰ñ“ûŠàŽ¡—ÃZƒ~ƒi[A‘åãA2007”N10ŒŽ 

 

iÀ’·j‘“cTŽO:ˆê”ʉ‰‘è@“û‘B‡UB ‘æ18‰ñ“ú–{“û‘Bbó‘B’´‰¹”gf’f‰ï‹c Aç—tA2007”N4ŒŽ

 

iŽi‰ïj‘“cTŽO: ‘‡“¢˜_Ži‰ï@2007”N“ûŠàŽ¡—Âðl‚¦‚éB ‘æ10‰ñ “ûŠàŽ¡—ÃZƒ~ƒi[A ‘åãA2007”N4ŒŽ

 

B-6

’Ë–{•¶‰¹AŽÅ@‰pˆêA‘“cTŽOA’†–ì–F–¾A•x‰iC·A¼•À“W‹PA–쑺FAŽR–{@mAˆäƒm–{‘ô–çA’†Œû˜a‘¥A¼@•q•vAÂ–ì@–LˆêA–k“c¹”VA“¿‰is•FA’†ŽR‹MŠ°A¼“cKOA•Ä“cŒõ—¢: uƒrƒXƒtƒHƒXƒtƒHƒl[ƒg—Ö@vu“ûŠàœ“]ˆÚÇ—á‚ɑ΂·‚éPamidronate 90mg’ZŽžŠÔ“Š—^‚̈À‘S«-‘½Ž{Ý‹¤“¯Œ¤‹†‚ÌŒ‹‰Ê‚©‚çvB  ‘æ117‰ñã_“û‘BŽ¾Š³’k˜b‰ïA‘åãA2007”NA3ŒŽ

 

B-7

’†X³“ñFäXŠà‰»Šw—Ö@‚ÌŒ»ó‚Æ‚»‚̍H•vB ‘æ18‰ñ –k—¤—Տ°Žîᇌ¤‹†‰ïAÎìA2007”N8ŒŽ

 

B-8

ã“cF•¶F‰^“®ŠíŽ¾Š³‚É‚¨‚¯‚éÅ‹ß‚̃gƒsƒbƒNƒX‚Æ“–‰È‚Å‚ÌŽæ‚è‘g‚݁B‘æ22‰ñ‚¨‚¨‚³‚©Œ’NƒZƒ~ƒi[A‘åãA2007”N9ŒŽ

 

ã“cF•¶F‘æII•”Fˆ««Ž¾Š³‚ÌŠÇ—‚ÆŽ¡—Â̊î–{Œ´‘¥ (13)œE“î•”B‘æ1‰ñ“ú–{‚ª‚ñŽ¡—ÔF’èˆã‹@\‹³ˆçƒZƒ~ƒi[A“Œ‹žA2008”N1ŒŽ

 

•ìK“TF˜_•¶‚̏‘‚«•ûBICRƒZƒ~ƒi[’†‹‰•ÒA“Œ‹žA2007”N4ŒŽ

 

•ìK“TFŠO‰ÈŽ¡—ÂƗՏ°ŽŽŒ±B“Œ‹ž—‰È‘åŠw—Տ°ŽŽŒ±u‰‰‰ïA“Œ‹žA2007”N6ŒŽ

 

•ìK“TF‚ª‚ñ‚ÌŽ¡—ÊJ”­‚ƗՏ°ŽŽŒ±‚̃fƒUƒCƒ“BDNAƒ`ƒbƒvŒ¤‹†Šu‰‰‰ïA‰¡•lA2007”N8ŒŽ

 

’†X³“ñFäX‚ª‚ñu‚Ç‚¤Ž¡—·‚évB ‘æ23‰ñ ‚¨‚¨‚³‚©Œ’NƒZƒ~ƒi[A‘åãA2007”N11ŒŽ

 

‘“cTŽO: “û‚ª‚ñ‚Ì‚¨‚Í‚È‚µB “ú–{ˆãŠw‘‰ïŠJÝu‚ª‚ñ‚ð’m‚é‘åã“WvA‘åãA2007”N4ŒŽ

 

‘“cTŽO: ƒOƒ‹[ƒvuK@uŽt‚𖱂߂éB ‘æ17‰ñƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒBuK‰ïA–¼ŒÃ‰®A2007”N5ŒŽ